Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Black Diamond Therapeutics, Inc.

BDTX Nasdaq SEC CIK 1701541
Follow Black Diamond Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$9.9M +6.2% vs same quarter last year
EPS, diluted −$0.17 +10.5% vs same quarter last year
Operating cash flow −$8M +13% vs same quarter last year
Revenue by quarter
$0
$0
$70M
$0
$0
$0
$0
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$75B−$50B−$25B$0$25BFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$70M$22.4B
FY24$0−$69.7B
FY23-−$82.4M
FY22-−$91.2M
FY21-−$125.6M
FY20$0−$67.3M
FY19$0−$35.3M
FY18$0−$8.9M
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$62.3M
FY23−$66.8M
FY22−$85.3M
FY21−$102.9M
FY20−$52.3M
FY19−$24.7M
FY18−$8.5M
FY17-

News

No stories filed under Black Diamond Therapeutics yet - coverage appears here as the news feed clusters it.